Skip To Content
BuzzFeed News Home Reporting To You

Utilizamos cookies, próprios e de terceiros, que o reconhecem e identificam como um usuário único, para garantir a melhor experiência de navegação, personalizar conteúdo e anúncios, e melhorar o desempenho do nosso site e serviços. Esses Cookies nos permitem coletar alguns dados pessoais sobre você, como sua ID exclusiva atribuída ao seu dispositivo, endereço de IP, tipo de dispositivo e navegador, conteúdos visualizados ou outras ações realizadas usando nossos serviços, país e idioma selecionados, entre outros. Para saber mais sobre nossa política de cookies, acesse link.

Caso não concorde com o uso cookies dessa forma, você deverá ajustar as configurações de seu navegador ou deixar de acessar o nosso site e serviços. Ao continuar com a navegação em nosso site, você aceita o uso de cookies.

The New Acting Chief Of The FDA Is A Cancer Scientist

Norman "Ned" Sharpless has publicly supported the agency's policies to curb the use of e-cigarettes.

Posted on March 12, 2019, at 1:14 p.m. ET

National Institutes of Health / Via Flickr: nihgov

Norman "Ned" Sharpless, the head of the National Cancer Institute and a cancer researcher and physician, will lead the Food and Drug Administration as acting commissioner, the Department of Health and Human Services announced on Tuesday.

Sharpless will take over for the current commissioner, Scott Gottlieb, who announced last week that he would resign — a departure that came as a surprise to many.

Sharpless will not necessarily have the job permanently, however. To become commissioner, he will have to be appointed by President Trump and confirmed by the Senate.

Trump appointed Sharpless to lead the National Cancer Institute, the agency that oversees cancer research within the National Institutes of Health, in the fall of 2017.

Before that, Sharpless was a cancer researcher and hematologist-oncologist at the University of North Carolina, where he had led the UNC Lineberger Comprehensive Cancer Center since 2014. He has conducted research into how normal cells age and turn into malignant tumors.

One of Gottlieb's most high-profile initiatives during his tenure was cracking down on the e-cigarette industry for fueling a rise in teen vaping. His departure raised concerns among public health advocates that the FDA would ease up on enforcement in his absence. But they may take comfort in the fact that Sharpless has publicly supported the agency's policies to curb the use of e-cigarettes.

His appointment may be less comforting news to e-cigarette manufacturers, however.

For those concerned @SGottliebFDA’s priorities on e-cigarettes/tobacco wouldn’t continue when he left, @NCIDirector Sharpless has been a supporter of those policies. Altria, Philip Morris International shares erased gains on the news. Here’s Altria

In Sharpless's place, the National Cancer Institute will be run by current deputy director Doug Lowy, according to the HHS.

A BuzzFeed News investigation, in partnership with the International Consortium of Investigative Journalists, based on thousands of documents the government didn't want you to see.